孕期暴露于注意力缺陷多动障碍药物。
Exposure to attention deficit hyperactivity disorder medications during pregnancy.
作者信息
Humphreys Caitlin, Garcia-Bournissen Facundo, Ito Shinya, Koren Gideon
出版信息
Can Fam Physician. 2007 Jul;53(7):1153-5.
Abstract
QUESTION
An 18-year-old patient of mine, currently under treatment for attention deficit hyperactivity disorder (ADHD) with methylphenidate, just found out that she is pregnant. What are the risks for the baby when the mother uses ADHD medications during pregnancy?
ANSWER
Available evidence for amphetamines suggests no increased risk of malformations with use of therapeutic doses, and inadvertent exposure during pregnancy is unlikely to be harmful. Human data for methylphenidate and atomoxetine treatment in pregnancy are very limited. Documented cases do not suggest teratogenicity, but we cannot rule out this risk with the information available.
摘要
问
我的一位18岁患者目前正在使用哌醋甲酯治疗注意力缺陷多动障碍（ADHD），她刚发现自己怀孕了。母亲在孕期使用治疗ADHD的药物对胎儿有哪些风险？
答
关于苯丙胺类药物的现有证据表明，使用治疗剂量时畸形风险不会增加，孕期意外接触不太可能有害。关于孕期使用哌醋甲酯和托莫西汀治疗的人体数据非常有限。已记录的病例未提示有致畸性，但根据现有信息我们不能排除这种风险。
相似文献
1
Exposure to attention deficit hyperactivity disorder medications during pregnancy.
Can Fam Physician. 2007 Jul;53(7):1153-5.
2
Treatment of adult ADHD and comorbid disorders.
CNS Spectr. 2006 Oct;11(10 Suppl 11):10-2. doi: 10.1017/s1092852900025773.
3
[The practice and problem of therapeutic agents for AD/HD].
No To Hattatsu. 2010 May;42(3):213-6.
4
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30.
5
Adverse Gestational Outcomes Associated With Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.
J Clin Psychiatry. 2018 Jan/Feb;79(1). doi: 10.4088/JCP.18f12136.
6
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000.
7
Pharmacological management of attention-deficit hyperactivity disorder.
Expert Opin Pharmacother. 2004 Jun;5(6):1313-20. doi: 10.1517/14656566.5.6.1313.
8
Current pharmacotherapy of attention deficit hyperactivity disorder.
Drugs Today (Barc). 2013 Oct;49(10):647-65. doi: 10.1358/dot.2013.49.10.2008996.
9
Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
BMC Psychiatry. 2011 Nov 10;11:176. doi: 10.1186/1471-244X-11-176.
10
Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2024 Nov 4;7(11):e2443648. doi: 10.1001/jamanetworkopen.2024.43648.
引用本文的文献
1
Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study.
Arch Womens Ment Health. 2024 Oct;27(5):785-794. doi: 10.1007/s00737-024-01450-4. Epub 2024 Mar 1.
2
Methylphenidate effects on mice odontogenesis and connections with human odontogenesis.
Odontology. 2021 Apr;109(2):336-348. doi: 10.1007/s10266-020-00548-2. Epub 2020 Aug 31.
3
Increasing use of ADHD medications in pregnancy.
Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):218-20. doi: 10.1002/pds.3742.
4
Off-label use of atomoxetine in adults: is it safe?
Ment Illn. 2012 Sep 24;4(2):e19. doi: 10.4081/mi.2012.e19. eCollection 2012 Jul 26.
5
ADHD treatment and pregnancy.
Drug Saf. 2014 Jun;37(6):397-408. doi: 10.1007/s40264-014-0168-5.
6
Response to Damkier.
Br J Clin Pharmacol. 2014 Jun;77(6):1084-5. doi: 10.1111/bcp.12237.
7
Prenatal tobacco, marijuana, stimulant, and opiate exposure: outcomes and practice implications.
Addict Sci Clin Pract. 2011 Jul;6(1):57-70.
8
Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats.
Neurosci Lett. 2011 Sep 20;502(3):152-6. doi: 10.1016/j.neulet.2011.07.013. Epub 2011 Jul 20.
本文引用的文献
1
Approach to attention deficit disorder in adults.
Can Fam Physician. 2006 Aug;52(8):961-4.
2
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine.
Birth Defects Res B Dev Reprod Toxicol. 2005 Dec;74(6):471-584. doi: 10.1002/bdrb.20048.
3
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidate.
Birth Defects Res B Dev Reprod Toxicol. 2005 Aug;74(4):300-81. doi: 10.1002/bdrb.20049.
4
Attention deficit hyperactivity disorder in teens and adults: they don't all outgrow it.
J Clin Psychol. 2005 May;61(5):529-33. doi: 10.1002/jclp.20117.
5
Pharmacotherapy of adult ADHD.
J Clin Psychol. 2005 May;61(5):589-606. doi: 10.1002/jclp.20122.
6
Attention-deficit/hyperactivity disorder in adults.
JAMA. 2004 Aug 4;292(5):619-23. doi: 10.1001/jama.292.5.619.
7
Drug therapy for adults with attention-deficit hyperactivity disorder.
Drugs. 2003;63(22):2395-411. doi: 10.2165/00003495-200363220-00002.
8
Atomoxetine and pregnancy.
J Am Acad Child Adolesc Psychiatry. 2003 Aug;42(8):883-4, author reply 884-5. doi: 10.1097/01.CHI.0000046902.27264.B8.
9
Attention-deficit/hyperactivity disorder in adults: an overview.
Biol Psychiatry. 2000 Jul 1;48(1):9-20. doi: 10.1016/s0006-3223(00)00889-1.
10
Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy.
Obstet Gynecol Clin North Am. 1998 Mar;25(1):119-38. doi: 10.1016/s0889-8545(05)70361-2.
Zotero 插件